Literature DB >> 6448024

Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.

D Kampf, R Schurig, K Weihermüller, D Förster.   

Abstract

The pharmacokinetics of mezlocillin were examined in 8 patients with normal renal function (inulin clearance, > 80 ml/min per 1.73 m2), 32 patients with moderately reduced renal function (inulin clearances, 80 to 5 ml/min per 1.73 m2), and 12 patients maintained by hemodialysis or peritoneal dialysis because of severely impaired renal function. A single dose of 60 mg of mezlocillin per kg of body weight was infused intravenously over 30 min. Antibiotic concentrations in plasma, urine, and dialysate were determined by the agar diffusion technique. The half-life of mezlocillin increased with decreasing renal function from an average of 53 min in subjects with normal function to 165 min in oligoanuric patients. The urinary recovery of this drug in 24 h decreased from 65% at a glomerular filtration rate of 92 ml/min to 7.6% at a glomerular filtration rate of 6.7 ml/min. Volume of distribution was not changed by the renal insufficiency, amounting on the average to 22.5% of body weight. Intermittent hemodialysis or peritoneal dialysis contributed to only a minor degree to the 24-h mezlocillin kinetics. The pharmacokinetic properties of mezlocillin permit a normal dosage over wide ranges of renal insufficiency; however, when the glomerular filtration rate is below 10 ml/min, the dosage interval should be increased from 8 to 12 h.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6448024      PMCID: PMC283943          DOI: 10.1128/AAC.18.1.81

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Body composition in chronic renal failure.

Authors:  G A Coles
Journal:  Q J Med       Date:  1972-01

2.  Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects.

Authors:  W J Jusko; G P Lewis; G W Schmitt
Journal:  Clin Pharmacol Ther       Date:  1973 Jan-Feb       Impact factor: 6.875

3.  Carbenicillin administration in patients with severe renal failure.

Authors:  J B Eastwood; J R Curtis
Journal:  Br Med J       Date:  1968-02-24

4.  Clinical pharmacological studies of carbenicillin.

Authors:  G P Bodey; V Rodriguez; D Stewart
Journal:  Am J Med Sci       Date:  1969-03       Impact factor: 2.378

5.  Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients.

Authors:  C M Kunin; Z Finkelberg
Journal:  Ann Intern Med       Date:  1970-03       Impact factor: 25.391

6.  Pharmacodynamics of carbenicillin in hepatic and renal failure.

Authors:  T A Hoffman; R Cestero; W E Bullock
Journal:  Ann Intern Med       Date:  1970-08       Impact factor: 25.391

7.  The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function.

Authors:  M M Reidenberg
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

8.  Kinetics of mezlocillin and carbenicillin.

Authors:  S J Pancoast; H C Neu
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

9.  The effects of peritoneal dialysis on the physiological disposition of oxacillin, ampicillin and tetracycline in patients with renal disease.

Authors:  J Ruedy
Journal:  Can Med Assoc J       Date:  1966-02-05       Impact factor: 8.262

10.  [Azlocillin and mezlocillin: two new semisynthetic acylureido-penicillins (author's transl)].

Authors:  H Lode; U Niestrath; P Koeppe; H Langmaack
Journal:  Infection       Date:  1977       Impact factor: 3.553

View more
  6 in total

Review 1.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Mezlocillin pharmacokinetics in pediatric oncology patients.

Authors:  W G Kramer; L K Pickering; S Culbert; L S Frankel
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

4.  Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.

Authors:  H Merdjan; A Baumelou; B Diquet; O Chick; E Singlas
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

5.  Improved micromethod for mezlocillin quantitation in serum and urine by high-pressure liquid chromatography.

Authors:  D Fiore; F A Auger; G L Drusano; V R Dandu; L J Lesko
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

6.  Mezlocillin disposition in chronic hemodialysis patients.

Authors:  D M Janicke; A Mangione; R W Schultz; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.